Photo of Ravi Shah

Partner in the General Corporate Practice at the Ahmedabad office of Cyril Amarchand Mangaldas. Ravi is dual-qualified in India and the UK having a wide range of experience working in both the jurisdictions. He primarily focuses on cross-border corporate transactions, mergers and acquisitions, joint ventures, private equity and venture capital investments, advising national and international clients.

He has also assisted clients on a range of complex commercial agreements including international franchising arrangements, project management and consultancy agreements, technology and data-center infrastructure agreements. His experience spreads across sectors including pharmaceuticals & healthcare, technology, FMCG, manufacturing, infrastructure, defense and aviation. He can be reached at ravi.shah@cyrilshroff.com

Gujarat - A Re-emerging Pharma Destination

Gujarat has been the flag bearer of India’s pharmaceutical industry since the establishment of the country’s second oldest drug company, the Alembic Chemical Works Company Limited in Vadodara in 1907. Gujarat’s strategic location on the western coast, coupled with dynamic entrepreneurial talent and favourable policies from the State Government has led it to become one of the premiere industrial hubs for investors looking to invest in India.

Gujarat currently has 33 percent of the aggregate share of the pharmaceutical industry in India[1] and the State also accounts for at least 28 percent of the pharmaceutical exports from India[2]. Moreover, with the advent of the Goods and Service Tax (GST) coupled with the upcoming expiry of tax holidays granted by some northern states of India, the pharmaceutical industry is witnessing a jurisdictional shift, with some of the largest pharmaceutical companies looking to relocate or establish their manufacturing plants in Gujarat.
Continue Reading